OOIR: Observatory of International Research

Papers

(The H4-Index of Lung Cancer is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma	98
HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours	86
Real-world use of nivolumab plus ipilimumab in the management of diffuse pleural mesothelioma (DPM): experience from the county of Kent	72
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study	61
Does consolidation radiotherapy to chest improve survival in extensive stage small cell lung cancer in the immunotherapy era? A retrospective study	60
Direct to CT screening pilot for patients with COPD in a deprived area: longitudinal analysis of the pulmonary nodule cohort outcomes	59
Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting	58
The role of mediastinoscopy following EBUS	53
Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma	52
Indwelling pleural catheter infections: a cautionary tale	52
Author index	51
Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study	49
The first historical description of malignant mesotheliomas	46
Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study	45
190 Localised non-small cell lung cancer: patient characteristics and radical radiotherapy outcomes according to KRAS mutation status	44
175 External Validation of a Left Anterior Descending Coronary Artery Dose Constraint in Patients with Non-Small Cell Lung Cancer: An NI–HEART Analysis	44
Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer	44
98 Hospitalisation Rates following Systemic Anti-Cancer Treatments for Patients with Non-Small Cell Lung Cancer	43
107 Osimertinib Efficacy in Advanced NSCLC Patients with PACC and Classical-Like EGFR Mutations: A Retrospective Analysis from The Christie	43
101 Treating advanced EGFR positive non-small cell lung cancer patients with Osimertinib - the University Hospital Plymouth experience	43
86 Real World Outcomes of Patients Receiving Neoadjuvant Treatment for Non-Small Cell Lung Cancer	42
74 The first-in-class PRX3 inhibitor RSO-021 modulates the composition of malignant pleural effusions by eliciting immunomodulation and decreasing epithelial to mesenchymal protein expression	42
89 Why do almost half of our patients not complete 12 months of maintenance durvalumab after successful radical chemoradiotherapy?	41
Title Page	36
251 Optimising engagement and addressing inequalities for patients using a Digital Behaviour Change Intervention in lung cancer prehabilitation: A mixed-methods study	35

260 Second Primary Lung Cancer Cohort Study (SPORT)	35
190 Decision Making for Thoracic Radiotherapy and Prophylactic Cranial Irradiation in ES-SCLC Post Chemoimmunotherapy	33
108 Evaluation of a Lung Cancer Nurse led clinic for the routine follow up of uncomplicated post resection lung cancer patients	33
Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportion	33
Evaluating lung cancer risk factors in adults with interstitial lung disease	32
Frailty, comorbidity and cardiovascular risk assessment in older patients with lung cancer	32
Contents	32
Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma	32
123 Using Prescribing Data to Estimate the Number of ALKpositive Patients Currently Living in England	32